Company research
Fortress Biotech, Inc.
CIK 1429260Updated Sep 26, 2026
Name history
Fortress Biotech, Inc. · through Sep 1, 2026CORONADO BIOSCIENCES INC · through Apr 27, 2015
FBIO price & chart
Loading TradingView…
NASDAQ:FBIO on TradingView ↗About the company
Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income. The company has a portfolio of multiple marketed prescription pharmaceutical products and programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Fortress’ portfolio is being commercialized and developed for various therapeutic areas including oncology, dermatology, and rare diseases. Fortress’ model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand and advance the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca, City of Hope, Nationwide Children’s Hospital, Columbia University, Dana-Farber Cancer Center and Sentynl Therapeutics. …
In the news
Fortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference ↗
CKPT Merger Alert: Checkpoint Shareholders Seeking Money Should Contact Julie & Holleman Regarding Sale to Sun Pharma News provided by Julie & Holleman LLP Mar 10, 2025, 18:41 ET Share this article Share to X Share this article Share to X NEW YORK , March 10, 2025 /PRNewswire/ -- Shareholder law fir ↗
--> Sun Pharma to Acquire Checkpoint Therapeutics News provided by Sun Pharmaceutical Industries Inc., USA (Sun Pharma) Mar 09, 2025, 22:06 ET Share this article Share to X Share this article Share to X (PRNewsfoto/Sun Pharmaceutical Industries Inc., USA (Sun Pharma)) Will add UNLOXCYT™ (cosibelimab ↗
Recent filings
SCHEDULE 13G filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Submission of Matters to a Vote of Security Holders
Items 5.07
10-Q filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 185,548,000Source | 144,223,000Source | 167,526,000Source | 294,301,000Source |
| Property, Plant and Equipment, NetUSD | 2,519,000Source | 3,260,000Source | 6,505,000Source | 13,020,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 79,381,000Source | 57,263,000Source | 80,927,000Source | 178,266,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 29,783,000Source | 10,231,000Source | 15,222,000Source | 28,208,000Source |
| Inventory, NetUSD | 9,624,000Source | 14,431,000Source | 10,206,000Source | 14,159,000Source |
| Assets, CurrentUSD | 123,841,000Source | 90,371,000Source | 117,022,000Source | 230,432,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 4,895,000Source | 7,110,000Source | 10,500,000Source | 9,661,000Source |
| Operating Lease, Right-of-Use AssetUSD | 12,302,000Source | 13,861,000Source | 16,990,000Source | 19,991,000Source |
| Other Assets, NoncurrentUSD | 401,000Source | 3,316,000Source | 4,284,000Source | 973,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 123,365,000Source | 145,867,000Source | 165,939,000Source | 244,276,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 3,000Source | 3,000Source | 3,000Source | 3,000Source |
| Common Stock, Value, IssuedUSD | 31,000Source | 28,000Source | 15,000Source | 110,000Source |
| Additional Paid in CapitalUSD | 783,891,000Source | 763,573,000Source | 717,396,000Source | 675,841,000Source |
| Retained Earnings (Accumulated Deficit)USD | -734,052,000Source | -740,867,000Source | -694,870,000Source | -634,233,000Source |
| Stockholders' Equity Attributable to ParentUSD | 49,873,000Source | 22,737,000Source | 22,544,000Source | 41,721,000Source |
| Liabilities and EquityUSD | 185,548,000Source | 144,223,000Source | 167,526,000Source | 294,301,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 49,744,000Source | 71,399,000Source | 84,908,000Source | 127,715,000Source |
| Operating Lease, Liability, CurrentUSD | 2,127,000Source | 2,623,000Source | 2,523,000Source | 2,447,000Source |
| Accounts Payable, CurrentUSD | 14,238,000Source | 31,636,000Source | 34,810,000Source | 57,244,000Source |
| Operating Lease, Liability, NoncurrentUSD | 12,672,000Source | 14,750,000Source | 18,282,000Source | 21,572,000Source |
| Deferred Income Tax Liabilities, NetUSD | — | — | 233,000Source | — |
| Other Liabilities, NoncurrentUSD | 1,447,000Source | 1,756,000Source | 1,893,000Source | 1,847,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | 12,310,000Source | -24,381,000Source | -20,957,000Source | 8,304,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 47,125,000Source | 65,501,000Source | 73,562,000Source | 97,446,000Source |
| Deferred Revenue, CurrentUSD | — | — | — | 728,000Source |
| Deferred Tax Liabilities, NetUSD | 280,000Source | 402,000Source | — | — |
| Long-term DebtUSD | 52,417,000Source | 57,962,000Source | 60,856,000Source | 91,730,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -32,915,000Source | -120,855,000Source | -154,154,000Source | -213,913,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 28,739,000Source | 32,619,000Source | 17,029,000Source | 22,987,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 19,341,000Source | -4,475,000Source | -12,551,000Source | 5,380,000Source |
| Increase (Decrease) in InventoriesUSD | -4,807,000Source | 4,225,000Source | -3,953,000Source | -1,744,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -65,777,000Source | -80,191,000Source | -128,225,000Source | -179,401,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 10,121,000Source | -15,000,000Source | -2,103,000Source | -22,928,000Source |
| Payments for (Proceeds from) Other Investing ActivitiesUSD | — | 0Source | 5,000Source | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | 0Source | 63,000Source | 2,715,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 77,442,000Source | 70,641,000Source | 32,739,000Source | 75,319,000Source |
| Payments of Ordinary Dividends, Common StockUSD | 664,000Source | 694,000Source | 736,000Source | 749,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 21,786,000Source | -24,550,000Source | -97,589,000Source | -127,010,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 80,601,000Source | 58,815,000Source | 83,365,000Source | 180,954,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 7,386,000Source | 7,159,000Source | 7,945,000Source | 9,419,000Source |
| Income Taxes Paid, NetUSD | 49,000Source | 120,000Source | -55,000Source | 858,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 28,739,000Source | 32,619,000Source | 17,029,000Source | 22,987,000Source |
| Amortization of Debt Issuance CostsUSD | 1,397,000Source | 1,939,000Source | 3,400,000Source | 2,065,000Source |
| Amortization of Intangible AssetsUSD | 4,258,000Source | 3,424,000Source | 3,767,000Source | — |
| Deconsolidation, Gain (Loss), AmountUSD | 27,127,000Source | — | — | — |
| DepreciationUSD | 403,000Source | 1,040,000Source | 2,230,000Source | 3,109,000Source |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | 15,075,000Source | — | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | 0Source | -29,000Source | 1,466,000Source | -255,000Source |
| Gain (Loss) on Termination of LeaseUSD | 394,000Source | — | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | 0Source | -2,457,000Source | -2,796,000Source | — |
| Income Tax Expense (Benefit)USD | -620,000Source | 312,000Source | 521,000Source | 449,000Source |
| Investment Income, InterestUSD | 2,485,000Source | 2,683,000Source | 3,003,000Source | 1,398,000Source |
| Net Income (Loss) Attributable to ParentUSD | 6,815,000Source | -45,997,000Source | -60,637,000Source | -86,575,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -39,730,000Source | -74,858,000Source | -93,517,000Source | -127,338,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -1,882,000Source | -55,890,000Source | -68,669,000Source | — |
| Nonoperating Income (Expense)USD | 36,686,000Source | -10,164,000Source | -11,291,000Source | -9,900,000Source |
| Operating Lease, ExpenseUSD | 1,200,000Source | 1,500,000Source | 1,900,000Source | 2,000,000Source |
| Other Nonoperating Income (Expense)USD | 17,578,000Source | 1,318,000Source | -3,403,000Source | — |
| Proceeds from Issuance of Common StockUSD | 1,008,000Source | 3,734,000Source | 2,041,000Source | 6,053,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 61,239,000Source | 55,134,000Source | 59,662,000Source | 70,995,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 63,262,000Source | 57,675,000Source | 84,513,000Source | 75,743,000Source |
| Cost of RevenueUSD | 20,924,000Source | 20,879,000Source | 26,660,000Source | 30,775,000Source |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 96,400,000Source | 87,731,000Source | 94,124,000Source | 113,656,000Source |
| Operating Income (Loss)USD | -70,221,000Source | -110,379,000Source | -142,342,000Source | -203,564,000Source |
| Other Nonoperating Income (Expense)USD | 17,578,000Source | 1,318,000Source | -3,403,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -33,535,000Source | -120,543,000Source | -153,633,000Source | -213,464,000Source |
| Income Tax Expense (Benefit)USD | -620,000Source | 312,000Source | 521,000Source | 449,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -39,730,000Source | -74,858,000Source | -93,517,000Source | -127,338,000Source |
| Net Income (Loss) Attributable to ParentUSD | 6,815,000Source | -45,997,000Source | -60,637,000Source | -86,575,000Source |
| Earnings Per Share, BasicUSD per share | -0.07Source | -2.69Source | -8.47Source | -0.97Source |
| Earnings Per Share, DilutedUSD per share | -0.07Source | -2.69Source | -8.47Source | -0.97Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 27,901,889Source | 20,784,334Source | 8,110,906Source | 88,874,519Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 27,901,889Source | 20,784,334Source | 8,110,906Source | 88,874,519Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 4,258,000Source | 3,424,000Source | 3,767,000Source | — |
| Costs and ExpensesUSD | 133,483,000Source | 168,054,000Source | 226,855,000Source | 279,307,000Source |
| Interest Expense, DebtUSD | 10,106,000Source | 13,527,000Source | 15,315,000Source | 12,482,000Source |
| Investment Income, InterestUSD | 2,485,000Source | 2,683,000Source | 3,003,000Source | 1,398,000Source |
| Net Income (Loss) Attributable to Nonredeemable Noncontrolling InterestUSD | 39,730,000Source | 74,858,000Source | 93,517,000Source | 127,338,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -1,882,000Source | -55,890,000Source | -68,669,000Source | — |
| Nonoperating Income (Expense)USD | 36,686,000Source | -10,164,000Source | -11,291,000Source | -9,900,000Source |
| Operating Lease, ExpenseUSD | 1,200,000Source | 1,500,000Source | 1,900,000Source | 2,000,000Source |
| Other IncomeUSD | 2,023,000Source | 1,000,000Source | 19,519,000Source | 2,674,000Source |
| Preferred Stock Dividends and Other AdjustmentsUSD | 8,697,000Source | 9,893,000Source | 8,032,000Source | — |
| Research and Development ExpenseUSD | — | — | 106,071,000Source | 134,876,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 61,239,000Source | 55,134,000Source | 59,662,000Source | 70,995,000Source |
Offerings
Registration 333-292154
Filing attachments
fbio-20260813xex99d1.htm · 8-K · 2026-08-13
EX-99.1 2 fbio-20260813xex99d1.htm EX-99.1 Exhibit 99.1 Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights Total net revenue increased 14% to $18.7 million for second quarter of 2026 compared to second quarter of 2025 Partnered programs continue to advance with Crystalys Therapeutics announcing its $130 million Series B financing to support the late-stage global development and commercialization preparation for dotinurad, and royalties generated…
Read attachment ↗fbio-20260113xex99d1.htm · 8-K · 2026-01-13
EX-99.1 2 fbio-20260113xex99d1.htm EX-99.1 Exhibit 99.1 Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred from Sentynl Therapeutics to Cyprium Cyprium eligible to receive tiered royalties and up to $129 million in aggregate development and sales milestones from Sen…
Read attachment ↗fbio-20250331xex99d1.htm · 8-K · 2025-03-31
EX-99.1 2 fbio-20250331xex99d1.htm EX-99.1 Exhibit 99.1 Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights Emrosi™ approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; initial distribution ongoing and first prescriptions filled Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; Checkpoint’s lead product, UNLOXCYT™, approved by FDA for the treatment of metastatic or locally advan…
Read attachment ↗